Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 27, 2026
Element Solutions (ESI) Falls -19.1% After $14.5 Billion Solstice Acquisition Announcement

Element Solutions (ESI) Falls -19.1% After $14.5 Billion Solstice Acquisition Announcement

Key Takeaways

  • Element Solutions shares declined approximately 19.1% over the past 30 days, falling from $45.66 to $36.93, driven primarily by the announced $14.5 billion acquisition by Solstice Advanced Materials.
  • The July 6 merger announcement triggered a sharp sell-off as investors questioned the deal's modest 15% premium and the combined company's diminished pure-play appeal in electronics chemicals.
  • Multiple analyst downgrades followed, including Mizuho cutting ESI to Neutral from Outperform with a price target reduction from $54 to $45, and Freedom Broker downgrading to Hold.
  • S&P Global Ratings placed both Element Solutions and Solstice on CreditWatch Negative, citing concerns about elevated pro forma leverage above 3.0x adjusted EBITDA.
  • Despite the sell-off, ESI's underlying electronics business continues to benefit from secular demand trends in semiconductors, AI infrastructure, and data center applications.

Element Solutions (ESI) Business Overview and Market Position

Element Solutions Inc is a leading global specialty chemicals company that supplies advanced material solutions across high-value industries including semiconductor fabrication, high-performance computing, automotive systems, consumer electronics, power electronics, communications infrastructure, aerospace and defense, and industrial surface finishing. The company's electronics segment—which accounts for approximately 73% of revenue—provides critical chemistries for chip interconnects, advanced packaging, circuit board assembly, and surface treatments. Its industrial and energy portfolio serves offshore energy, automotive, and general industrial end markets. Investors closely track ESI for its exposure to secular growth themes in AI-driven computing, data center expansion, and increasing semiconductor content across industries.

Element Solutions (ESI) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ESI shares fell approximately 19.1%, from a closing price of $45.66 on June 26, 2026, to $36.93 on July 27. The descent was not gradual—shares traded near $49 in late June before the acquisition announcement on July 6 triggered an abrupt repricing. The stock plunged from $42.32 on July 6 to $38.57 on July 7, marking one of the sharpest two-day declines in the company's recent history. Over the broader quarter, ESI initially rallied strongly on AI and semiconductor tailwinds, reaching a 52-week high of $49.25 in late June, before the merger-related sell-off erased most of those gains. The stock now trades well below the implied merger consideration of approximately $50.10 per share, reflecting persistent market skepticism about deal completion and valuation.

What Drove ESI Stock Price in the Last 30 Days

The dominant catalyst was the July 6 announcement that Solstice Advanced Materials (SOLS) would acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion, including assumed net debt. Under the terms, ESI shareholders would receive $10.00 in cash and 0.500 shares of SOLS common stock per ESI share—implying roughly $50.10 per share, a premium of only about 15% over the July 2 closing price. Rather than rallying toward the deal price, ESI shares sold off as the market absorbed several concerns: the modest premium relative to the stock's strong year-to-date gains, the loss of pure-play electronics chemicals exposure, and uncertainty around the combined entity's valuation. Mizuho downgraded ESI to Neutral on July 15, slashing its price target to $45 from $54, noting that shareholders "may have been hoping for a path to pure-play electronic chemicals." Freedom Broker and UBS followed with downgrades and target reductions. S&P Global Ratings placed both companies on CreditWatch Negative on July 8, citing pro forma leverage that could rise well above 3.0x. Meanwhile, SOLS shares fell even more sharply—over 20%—amplifying the effective value of the stock component of the deal and further pressuring ESI. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Drove ESI Stock Performance Over the Last Quarter

Prior to the merger announcement, Element Solutions enjoyed strong upward momentum driven by robust demand in its electronics segment. The company reported first-quarter 2026 earnings of $0.41 per share on revenue of $840 million, beating consensus estimates by 7.9% and 18.2% respectively. Acquisitions—including Micromax from Celanese and EFC Gases and Advanced Materials—expanded the company's product portfolio and strengthened its position in semiconductor fabrication and advanced packaging. Several analysts raised price targets earlier in the quarter: BofA Securities lifted its target to $48, and Truist Securities increased its target to $47, both citing organic growth momentum and AI-related demand tailwinds. The stock's strong year-to-date gain of over 63% at its peak reflected investor enthusiasm for specialty chemical companies leveraged to the AI infrastructure buildout. The merger announcement abruptly shifted the narrative from organic growth to deal uncertainty, compressing what had been an expanding valuation premium.

ESI Stock Forecast Drivers: What Investors Should Watch Next

Investors should closely monitor Element Solutions' second-quarter 2026 earnings report, released after the market close on July 27, with the conference call scheduled for July 28. Analysts expect earnings of $0.43 per share on revenue of $873.31 million, and management commentary on demand trends in semiconductor fabrication and AI-related applications will be critical for assessing standalone business momentum. The merger integration planning timeline and any regulatory updates—particularly regarding antitrust reviews—will influence the perceived probability of deal completion, expected in the first half of 2027. The wide gap between ESI's current trading price and the implied $50.10 merger consideration reflects material deal-completion risk; narrowing or widening of this spread will depend on regulatory signals and any competing bid developments, though Mizuho has characterized the probability of a third-party offer as low. Macroeconomic conditions, including interest rate policy and semiconductor industry cyclicality, remain important background factors that could affect both standalone performance and the combined company's post-merger outlook. Solstice's ability to execute on its deleveraging plan and achieve the targeted $180 million in net cost synergies within three years of closing will be pivotal to the long-term value proposition for ESI shareholders who will own approximately 44% of the combined entity.

Navigating Volatility with AI Trading Tools

In volatile situations like the recent moves in ESI, I find Tickeron’s Trending AI Robots helpful for reviewing data-driven strategies. The platform features top-performing AI trading bots across different timeframes and risk profiles, with transparent performance metrics and trade histories. This allows for a clearer view of how various approaches have handled M&A-driven market shifts and sector rotations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ESI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ESI's RSI Indicator ascends from oversold territory

The RSI Oscillator for ESI moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In of the 24 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on ESI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESI just turned positive on August 04, 2026. Looking at past instances where ESI's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESI advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

ESI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

ESI moved below its 50-day moving average on July 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ESI crossed bearishly below the 50-day moving average on July 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ESI entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.330) is normal, around the industry mean (7.221). P/E Ratio (51.932) is within average values for comparable stocks, (38.970). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.399). Dividend Yield (0.008) settles around the average of (0.019) among similar stocks. P/S Ratio (2.965) is also within normal values, averaging (95.496).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.09B. The market cap for tickers in the group ranges from 47 to 226.36B. LIN holds the highest valuation in this group at 226.36B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was 6%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 8%. FEAM experienced the highest price growth at 57%, while CC experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 34%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
ESI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of technology chemical products and technical services

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
500 East Broward Boulevard
Phone
+1 561 207-9600
Employees
5300
Web
https://www.elementsolutionsinc.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.